Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that P50 auditory evoked potentials can be recorded across multiple sites and reliably demonstrate a physiological abnormality in schizophrenia.
|
20382002 |
2010 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence of normalized auditory P50 suppression with acute nicotine in schizophrenia has supported the contention that elevated smoking rates in this disorder may be an attempt to correct a nicotinic receptor pathophysiology that may underly impaired sensory gating in these patients.
|
19961902 |
2010 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gating of the theta-alpha-frequency oscillatory signal in the paired-click paradigm is more strongly associated with schizophrenia and has significantly higher heritability compared with the traditional P50 gating.
|
18762587 |
2008 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The alpha7 nicotinic acetylcholine receptor gene (CHRNA7) is located at 15q13-q14 in a region that is strongly linked to the P50 sensory gating deficit, an endophenotype of schizophrenia and bipolar disorder.
|
18545269 |
2008 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In persons with bipolar type schizoaffective disorder, CHRNA7 promoter region allelic variants are linked to the capacity to inhibit the P50 auditory evoked potential and thus are associated with a type of illness genetically and biologically more similar to schizophrenia.
|
17192894 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in sensory gating measured by the suppression of P50 auditory event-related potential (ERP) has been implicated in the biological bases of schizophrenia and some other psychiatric disorders and proposed as a candidate endophenotype for genetic studies.
|
17014995 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to the Colorado studies in the non-Colorado studies P50 suppression would not qualify as an endophenotype for schizophrenia.
|
17604606 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All four event-related potential indices are potentially valid endophenotypes for schizophrenia, but P50 suppression and P300 amplitude show the closest genetic relationship to schizophrenia.
|
17475740 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
DMXBA is well tolerated in humans and a new study in persons with schizophrenia has found that DMXBA enhances both P50 auditory gating and cognition. alpha7 Nicotinic acetylcholine receptor agonists appear to be viable candidates for the treatment of cognitive disturbances in schizophrenia.
|
17349863 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several previous studies have reported a significant linkage between markers in the alpha 7 nicotinic cholinergic receptor subunit (CHRNA7) gene and either schizophrenia or the P50 sensory gating deficit, a schizophrenia endophenotype.
|
17113175 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-five comparison and 42 schizophrenia subjects underwent P50 gating measurement and COMT genotyping.
|
17448448 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three physiological inhibitory endophenotypes of large effect size in schizophrenia include suppression of P50 auditory evoked responses, inhibition of leading (small anticipatory) saccades during smooth pursuit eye movements, and cancellation of reflexive saccades in the antisaccade eye movement task.
|
18056246 |
2007 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 2bp deletion in exon 6 of CHRFAM7A, which disrupts the hybrid gene and has previously been associated with P50 deficit, was genotyped in 251 individuals from the Maudsley Family Study of schizophrenia.
|
17012698 |
2006 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the P50 and N100 decrease correlated with the unaffected subjects' genetic resemblance to schizophrenia patients.
|
16876141 |
2006 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that, despite the prominent role that P50 abnormalities have played in our understanding of schizophrenia, there is a relative dearth of data examining P50 clinical correlates.
|
16469942 |
2006 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The locus is unusual in that it was first linked to an endophenotype found in schizophrenia, the P50 deficit, and subsequently to schizophrenia.
|
16843094 |
2006 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diminished suppression of the P50 auditory evoked potential is a phenotype used in studies of genetic susceptibility in schizophrenia.
|
15625200 |
2005 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A number of studies have suggested that the alpha-7-nicotinic receptor D15S1360 polymorphism is associated with schizophrenia and a deficiency in the normal inhibition of the P50 auditory-evoked response.
|
15100704 |
2004 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subjects with schizophrenia and half their first-degree relatives have deficits in sensory gating, with P50 ratios that are generally greater than 50%.
|
15465979 |
2004 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As suggested by several studies, abnormal sensory gating measured by the P50 paradigm could be an endophenotype predisposing to schizophrenia.
|
14569275 |
2004 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because P50 sensory gating deficit is a common neurophysiological dysfunction in patients with schizophrenia and schizophrenia spectrum disorders, it is conceivable to hypothesize that the human alpha7 neuronal nicotinic receptor subunit gene might be a susceptible gene for schizophrenia.
|
15531077 |
2004 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the genetically HR group, abnormal P50 sensory gating was found only in offspring who met criteria for the schizophrenia prodrome.
|
15038993 |
2004 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the core promoter of the gene are associated with schizophrenia and also with diminished inhibition of the P50 response.
|
12685995 |
2003 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A paired-stimulus auditory event- related potential paradigm was used to examine P50 sensory gating in 85 schizophrenia patients (56 medicated with typical antipsychotics and 29 unmedicated), 83 of their first-degree relatives (46 parents and 37 siblings), and 29 normal comparison subjects.
|
12450949 |
2002 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormality in the P50 auditory-evoked potential gating is an endophenotype associated with schizophrenia.
|
12399955 |
2002 |